Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02159495

Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

This phase I trial studies the side effects and the best dose of genetically modified T-cells after cyclophosphamide in treating patients with relapsed or refractory acute myeloid leukemia. An immune cell is a type of blood cell that can recognize and kill abnormal cells in the body. The acute myeloid leukemia-specific immune cell product will be made from patients' blood cells. The immune cells are changed by inserting additional pieces of deoxyribonucleic acid (DNA) (genetic material) into the cell to make it recognize and kill acute myeloid leukemia cells. Placing a modified gene into white blood cells may help the body build an immune response to kill cancer cells.

Status: 
Recruiting
Study Date: 
Tue, 12/01/2015 to Fri, 12/01/2017
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Drug: cyclophosphamide Given IV Other Names: CPM CTX Cytoxan Endoxan Endoxana Biological: anti CD123-CAR/CD28-costimulatory, lentiviral vector-transduced autologous T lymphocytes Given IV Other Name: CD123R(EQ)28zeta/EGFRt+ T cells Other: laboratory biomarker analysis Correlative studies Drug: Etoposide Given IV Other Names: Demethyl Epipodophyllotoxin Ethylidine Glucoside EPEG Lastet Toposar Vepesid VP-16 Drug: Fludarabine Phosphate Given IV Other Names: 2-F-ara-AMP 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)- Beneflur Fludara Oforta SH T 586 Biological: Therapeutic Allogeneic Lymphocytes Given allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes IV Other Name: Allogeneic Lymphocytes